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patients with type 2 diabetes and nephropathy over 3.4 years. The clinical outcome 
data were based on the results from the RENAAL trial. Direct medical costs referred 
to the purchase costs of losartan and the cost of National Health Service (NHS) hos-
pitalization. The costs were discounted back at an annual rate of 3%. Also sensitivity 
analysis was performed. RESULTS: RENAAL study establishes that losartan, along 
with conventional antihypertensive treatment as needed, confers strong renal protec-
tion in patients with type-2 diabetes and nephropathy. Globally, the total cost over 
42 months of follow-up was estimated at 9.802,49 a in the losartan and a13,405,47 
in the placebo group, resulting into a cost saving of a3602.98 per patient. Results 
were robust to both clinical and economic variables. CONCLUSIONS: In addition to 
the medical beneﬁt, this analysis demonstrated the economic relevance of treatment 
with losartan in type 2 diabetic patients with nephropathy.
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OBJECTIVES: A recently published health technology appraisal (NICE guidance 57) 
on continuous subcutaneous insulin infusion (CSII) therapy considered observational 
studies to complement RCTs in the assessment of effectiveness of CSII in type 1 dia-
betes patients. Observational studies showed signiﬁcantly higher improvements in       
HbA1c levels with CSII compared to multiple daily injections (MDI) as available RCTs       
did. Furthermore, a statistically signiﬁcant decrease of severe hypoglycaemic episodes 
has been stated. Our model based analysis assessed the clinical and economical impact          
in Germany. METHODS: The following baseline assumptions were applied within 
our validated type 1 diabetes model: (1) patient characteristics at simulation start (age 
26 years, duration of diabetes 12 years, baseline HbA1c 8.7%,); (2) a HbA1c improve-
ment by CSII compared to MDI of 0.6% (RCTs) and 1.2% (observational); (3) 
reduction of severe hypoglycemic events by 50%; (4) costs for insulin pumps a3,680 
during an amortization period of 4 years; (5) annual costs for infusion sets a1,040. 
RESULTS: With CSII total life time costs per patient increased by a50,967 / a36,873 
with an HbA1c reduction of 0.6% / 1.2%. Life expectancy increased by 0.99 / 2.00 
years, respectively. In consequence RCTs yield to an incremental cost-effectiveness 
ratio (ICER) of a51,736 and observational studies to a18,359 per life year gained. 
Life time cumulated costs for nephropathy and amputation with CSII compared 
to MDI decreased by a10,787 / a22,967 and a1,183 / a2,462, respectively. 
CONCLUSIONS: The NICE appraisal judged observational data in CSII as better 
resembling the population in routine care. Data derived from observational studies 
indicate that HbA1c-reductions can be distinctly higher than described in RCTs. In 
consequence the ICER could improve considerably. In the underlying analysis the 
additional costs for insulin pump and consumables are partially compensated by the 
reduced complication-related costs due to the improved glycemic control in CSII 
therapy.
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OBJECTIVES: A multicentre, randomised, double-blind, placebo-controlled clinical 
trial was conducted in Japanese impaired glucose tolerance (IGT) population to evalu-
ate the effect of preventing the development of type-2 diabetes mellitus (T2DM), and 
a signiﬁcant effect of voglibose in preventing the development of T2DM was conﬁrmed 
compared to the placebo. The objective of this analysis was to estimate the cost-
 effectiveness of administering voglibose in addition to standard care of diet and exer-
cise compared to standard care alone for high-risk Japanese individuals with IGT. 
METHODS: An annual cycle Markov model was constructed to estimate the long-
term prognosis of individuals with IGT (56-years-old), in terms of expected medical 
costs, and life expectancy. The Markov model consisted of ﬁve stages: normal glucose 
tolerance, IGT, T2DM, dialysis and death. Transition probabilities were derived from 
the results of the voglibose clinical trial as well as the epidemiological information. 
Costs included the drug acquisition cost of voglibose, IGT management cost, annual 
medical costs of T2DM and cost of dialysis. Effectiveness was evaluated by life expec-
tancy. The future costs and effectiveness were discounted by 3% per year. RESULTS: 
Expected lifetime costs for the voglibose administration group and the standard care 
group were calculated at JPY718,724 (a5,380) and JPY1,365,405 (a10,220) respec-
tively, with voglibose administration resulting in an estimated saving of JPY646,681 
(a4,840). Life expectancy was calculated at 18.672 years and 18.073 years respec-
tively, with life expectancy prolonged by 0.599 years when voglibose was administered 
along with the standard care. CONCLUSIONS: In order to prevent T2DM among 
Japanese individuals with IGT, intervention by voglibose together with the standard 
care for life-style modiﬁcation resulted in the expectation of long-term cost-saving, as 
well as prolongation of life expectancy, compared to the standard care of conducting 
only diet and exercise therapies.
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OBJECTIVES: CHD, DMT2 and COPD constitute an enormous burden of disease 
due to high prevalence, severe co-morbidities, increased mortality and high costs for 
society. Smoking is a main risk factor for developing the mentioned diseases and has 
a major impact on the disease development. Aim of the presented study was to analyze 
the incremental cost-effectiveness ratios (ICER) of smoking cessation with NRT com-
pared to Placebo/no intervention for patients with CHD, DMT2 and COPD. 
METHODS: The ICERs were calculated for each study population by use of separate 
Markov-Models. Patient started the models in the age of 45 years and undertake a 
single quit attempt with NRT or Placebo/no intervention. According to the likelihood 
of success, the diseases’ long-term natural courses are simulated for either smokers or 
ex-smokers. Input data such as success rate of smoking quit attempt, transition prob-
abilities, costs (base year 2008) are based on systematic literature researches and 
internal calculations. From the perspective of the German Statutory Health System, 
incremental costs per life-year gained (LYG) are calculated. Assumptions and uncer-
tain parameters are set conservatively and tested in multiple sensitivity analyses. 
RESULTS: Within a simulated time horizon of 55 years, smoking cessation with NRT 
is the dominant strategy: in all indications, NRT leads to additional LYGs at lower 
costs compared to Placebo/no intervention. NRT remains the dominant strategy 
throughout most sensitivity analyses. The parameters of highest inﬂuence on the 
outcome are the effectiveness of both strategies and additionally considered costs for 
smokers. CONCLUSIONS: NRT is a cost-effective treatment option for smoking 
cessation compared to Placebo or no intervention in patients with CHD, diabetes and 
COPD. The results of these analyses are robust to the variation of numerous model 
parameters and assumptions.
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OBJECTIVES: To project long term costs and outcomes for continuous subcutaneous         
insulin infusion (CSII) compared with multiple daily injections (MDI) of insulin in 
adult type-1 diabetes mellitus (T1DM) patients in Italy from the National Health 
Service (NHS) perspective. METHODS: The CORE Diabetes Model (CDM) was used 
to determine the incremental cost-effectiveness ratio (ICER) of CSII compared with 
MDI among adult patients with T1DM in Italy. The primary input variable was 
change in HbA1c and assumed to be a 1.2% improvement for CSII as compared to 
MDI in a cohort of Italian T1DM patients with an average HbA1c baseline value of 
8.95%. It was also assumed that CSII patients had 50% less hypoglycemic events 
compared with MDI patients. A series of Markov constructs simulated the progression 
of diabetes-related complications. The average annual cost for CSII and MDI were 
a5699.20 and a2734.71, respectively. The costs were derived from Italian-speciﬁc 
sources and other published data. A 60-year time horizon and a discount rate of 3.0% 
per annum on costs and clinical outcomes were used. RESULTS: Treatment with CSII 
was associated with improvements in life expectancy of 0.981 years vs. MDI and 
quality adjusted life year (QALY) of 1.063 years vs. MDI with corresponding ICERs 
of a34,541 per life-year and a31,879 per quality-adjusted life year (QALY) gained for 
CSII compared with MDI. The cumulative incidence of end-stage renal disease (ESRD) 
was reduced by 18% (RR  0.816) with a NNT of 22 patients to avoid one case of 
ESRD.while cumulative incidence of peripheral vascular disease (PVD) was reduced 
by 14% (RR  0.856); with a NNT of 46 patients to avoid one case of PVD. CON-
CLUSIONS: Setting the willingness to pay at a40,000/QALY (based on a £30,000 
NICE threshold), CSII is a cost-effective treatment option when compared to MDI for 
adult patients with T1DM in Italy.
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OBJECTIVES: To compare the direct treatment costs in insulin-naïve type-2-diabetics 
(T2D) starting a basal supported oral therapy (BOT) with either insulin glargine (GLA) 
or NPH-insulin (NPH) over 10 years focusing on the different persistence to these 
regimens. METHODS: A cost-minimization approach was applied. The analysis was 
conducted from the German statutory health insurance (SHI) perspective. A Markov 
model was developed simulating the onset of a BOT with GLA or NPH at a ratio of 
1:1 and thereafter switching to an intensiﬁed conventional therapy (ICT) with the 
same basal insulin in the course of 10 years. Persistence data were obtained from the 
IMS Disease Analyzer database [1] considering the ﬁrst 6 months after starting BOT 
as titration phase. Cost data were derived from a German cost evaluation in an 
